Search | Clinical Trials Finder

Conditions: Endometriosis Related Pain
Interventions: Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 43
States / cities: Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more

Conditions: Prostate Cancer, Advanced Prostate Cancer, Hormone Sensitive Prostate Cancer
Interventions: Darolutamide, Relugolix; Drug
Lead sponsor: Atish Choudhury, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Relugolix/E2/NETA FDC, Relugolix, Erythromycin; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Contraception
Interventions: Relugolix Combination Therapy; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 109
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 89 more

Conditions: Prostate Cancer
Interventions: Relugolix, Leuprolide Acetate; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 108
States / cities: Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 83 more

Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin; Drug · Procedure · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2,753 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2038
U.S. locations: 594
States / cities: Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more

Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, Fluciclovine F18, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography, PSMA PET Scan, Relugolix, Stereotactic Body Radiation Therapy; Procedure · Other · Drug + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2034
U.S. locations: 242
States / cities: Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 192 more

Conditions: Healthy
Interventions: Relugolix, E2/NETA; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Endometriosis, Pelvic Pain
Interventions: Relugolix CT; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
Interventions: Relugolix + Estradiol + Norethindrone Acetate; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Marlborough, Massachusetts

Conditions: Prostate Cancer
Interventions: FTLEAD, Ultra-Short-Term Androgen Deprivation Therapy with Relugolix, HypoLEAD, ADT Standard of Care; Radiation · Drug
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 85 Years · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Prostate Cancer
Interventions: Relugolix, Leuprorelin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 19
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more

Conditions: Prostate Adenocarcinoma
Interventions: Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin; Drug · Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 567
States / cities: Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more

Conditions: Cervical Mucus
Interventions: Gonadotropin Releasing Hormone Antagonists Relugolix; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Prostate Cancer, Stage IV Prostate Cancer
Interventions: Luteinizing Hormone Releasing Hormone, New Hormonal Agent, Docetaxel, Tislelizumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Prostate Cancer
Interventions: Relugolix, Leuprolide Acetate; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 27
States / cities: Tucson, Arizona • Orange, California • Denver, Colorado + 24 more

Conditions: Prostate Cancer
Interventions: DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Enzalutamide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Neuroendocrine Prostate Cancer
Interventions: [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Omaha, Nebraska • New York, New York

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium, Laparoscopic Radical Prostatectomy with Robotics, Pelvic Lymphadenectomy, Positron Emission Tomography, Relugolix; Procedure · Other · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Pelvic Pain
Interventions: Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 35 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Prostate Cancer
Interventions: Relugolix 120 MG [Orgovyx], SBRT standard of care radiotherapy treatment; Drug · Radiation
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: New Haven, Connecticut • Lebanon, New Hampshire • New York, New York + 1 more

Conditions: Prostate Cancer, Prostate Cancer Metastatic, Prostate Adenocarcinoma
Interventions: Relugolix Pill, Ritonavir, Itraconazole; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants

The COSMYC Trial (COmbined Suppression of MYC)

Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

The University of Miami Adapt (UAdapt) Trial

A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Insights in Endocervical Mucus Secretion

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients